Anaemia: causes, symptoms and treatment

Written by: Dr Michael Potter
Published:
Edited by: Jay Staniland

 

Anaemia refers to a low haemoglobin level in the blood. Haemoglobin in the main pigment found in red cells, which carries oxygen from the lungs to the tissues. Each laboratory will have a normal range for haemoglobin levels in men and women.

 

 

Symptoms of anaemia:

 

  • Fatigue
  • Shortness of breath – particularly on exertion
  • Dizziness
  • Poor appetite
     

Anaemia is a significant problem for patients who have intercurrent cardiac or lung problems, such as angina or breathlessness from chronic pulmonary disease. The anaemia may exacerbate symptoms such as chest pain in angina or breathlessness in patients with heart failure or chronic lung disease.

 

Pernicious vs. severe anaemia

Pernicious anaemia

 

Pernicious anaemia is one type of anaemia caused by a deficiency of vitamin B12. Vitamin B12 helps the body to make healthy red cells. It is found mainly in animal foods including meat, fish, eggs and dairy products. The haemoglobin level is low and the red cell size or MVC is often raised. A low vitamin B12 level is measured in the blood. In a patient with pernicious anaemia it is important to investigate the underlying cause, which, for example could be dietary such as in a vegan patient. It can be due to malabsorption or abnormalities in the gastrointestinal tract and also auto-immune diseases.
 

It is important to diagnose vitamin B12 deficiency as other problems can occur aside from anaemia, such as complications with the nervous system. Treating pernicious anaemia is usually simply a matter of replacing vitamin B12, typically by occasional injections of vitamin B12 intramuscularly. Sometimes oral vitamin B12 can be used if the absorption process is not affected.

 

Severe anaemia

 

Severe anaemia is different from pernicious anaemia. There is no generally accepted level of haemoglobin which is classified as severe anaemia. An anaemia that is causing significant symptoms in the patient, or other signs such as a rapid heartbeat or cardiac problems, could classify this as severe. For most healthy people, a haemoglobin level of 80g/L or above is generally well tolerated but this is not necessarily the case for patients with intercurrent heart or lung problems.

 

Treatment of anaemia

 

Treatment of this condition can only be commenced when the underlying cause is recognised. Anaemia in itself is not a diagnosis. It reflects a disease process with either underproduction of red cells or increase destruction of red cells. A blood transfusion will increase haemoglobin levels quickly, but without addressing the underlying causes of anaemia the haemoglobin will slowly fall.
 

Erythropoietin is a hormone produced by the kidney which regulates red cell formation in the bone marrow. Injections of erythropoietin can easily be given subcutaneously and this can boost haemoglobin levels. This is applicable to some patients with anaemia. For the majority however the treatment is directed against the underlying cause, for example, this can be by taking iron or vitamin supplements such as vitamin B12 or folic acid.

 

Is anaemia preventable?

 

Dietary anaemia is preventable and this is a relatively common cause of anaemia worldwide. Adequate intake of iron, vitamin B12 and folic acid are required. This can be achieved by a mixed healthy diet. Vegetarians or vegans are prone to iron and / or vitamin B12 deficiency and individuals with poor intake of vegetables can be prone to folic acid deficiency.
 

Excessive alcohol intake can exacerbate anaemia. Anaemia can also be due to chronic blood loss and patients should always report symptoms of this if noticed to their doctor e.g. bleeding from the bowel or heavy menstrual periods.

By Dr Michael Potter
Haematology

Dr Michael Potter is a highly experienced haematologist with over 20 years' experience as a specialist consultant in his field and practises at prominent institutions in London. He specialises in stem cell transplantation, chemotherapy, leukaemia, lymphoma, mieloma, myelodysplasia and myeloproliferative disorders and has a special interest in investigating possible blood disorders such as abnormal blood cell or platelet counts. 

Dr Michael Potter qualified with a BA/MA from Cambridge University in 1981 and a MB/BS from the London University in 1984. He then undertook his haematology training across the UK and went on to complete a PhD at the University of Bristol on the detection of minimal disease in acute lymphoblastic leukaemia in 1993. He earned his fellowship to the Royal College of Physicians in 2001.  

He is head of the transplant programmes at The Royal Marsden and The London Clinic. The transplant programme at The Royal Marsden is the largest programme in the UK, with over 200 transplants being performed annually.

He is also the programme director for the Stem Cell Transplant programme at the London Clinic, which is the only hospital that possesses a fully accredited JACIE unit in the UK. This programme is one of the largest in Europe, collecting approximately 800 annual donor collections.
 
In his role as a full-time clinician, he treats patient with chemotherapy and new agencies for a wide range of haematological malignancies and other blood conditionings. He works with a vasty experienced multidisciplinary team to provide the best care and advice in terms of diagnosis and treatment.
 
His personal feedback from patients is outstanding. He is known for communicating with patients in a friendly, clear, honest and empathic manner, as well as providing patients with a positive outlook in difficult times.
 
Dr Potter is dedicated to research which is centred on improving treatment outcomes for patients and has been widely published in over 160 peer-reviewed journals.
 
This year Dr Potter, along with his colleagues showcased world-leading blood cancer therapy at Arab Health 2023. Speaking about immunotherapy, Dr Potter states that incredibly, with this therapy doctors ‘can cure otherwise incurable cancer in groups of patients who have essentially run out of treatment options.’ He claims that up to 50 per cent of patients who have received CAR-T cell therapy are now cured.
 
Dr Potter is part of several medical organisations, including The American Society for Haematology and The European Blood and Marrow Transplant Group. He is an executive member of the British Society for Blood and Marrow Transplantation Blood and Marrow Transplant Group.
 
Suspected/confirmed cancer diagnosis only to be seen at The Royal Marsden Hospital. GP or hospital referral letter required for appointments.  All other diagnoses please enquire via The London Clinic or Mount Alvernia Hospital.

View Profile

Overall assessment of their patients


  • Related procedures
  • Thrombosis
    Growth factors
    Bone marrow cancers
    Pancreatic cancer
    Pulmonary embolism
    Immunotherapy
    Anaemia
    Alteration of red blood cells
    Multiple myeloma
    Myelodysplastic syndrome
    This website uses our own and third-party Cookies to compile information with the aim of improving our services, to show you advertising related to your preferences as well analysing your browsing habits. You can change your settings HERE.